JP2019501876A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501876A5 JP2019501876A5 JP2018524832A JP2018524832A JP2019501876A5 JP 2019501876 A5 JP2019501876 A5 JP 2019501876A5 JP 2018524832 A JP2018524832 A JP 2018524832A JP 2018524832 A JP2018524832 A JP 2018524832A JP 2019501876 A5 JP2019501876 A5 JP 2019501876A5
- Authority
- JP
- Japan
- Prior art keywords
- physiologically acceptable
- acceptable excipient
- mixture
- micronized particles
- carrier
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 36
- 239000002245 particle Substances 0.000 claims description 28
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 25
- 238000009472 formulation Methods 0.000 claims description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 16
- 229960002462 glycopyrronium bromide Drugs 0.000 claims description 10
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 9
- 229950000210 beclometasone dipropionate Drugs 0.000 claims description 9
- 239000011362 coarse particle Substances 0.000 claims description 9
- RATSWNOMCHFQGJ-TUYNVFRMSA-N (e)-but-2-enedioic acid;n-[2-hydroxy-5-[(1s)-1-hydroxy-2-[[(2s)-1-(4-methoxyphenyl)propan-2-yl]amino]ethyl]phenyl]formamide;dihydrate Chemical compound O.O.OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 RATSWNOMCHFQGJ-TUYNVFRMSA-N 0.000 claims description 8
- 229960003610 formoterol fumarate dihydrate Drugs 0.000 claims description 8
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 229940112141 dry powder inhaler Drugs 0.000 claims description 5
- 239000011882 ultra-fine particle Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims 13
- ANGKOCUUWGHLCE-UHFFFAOYSA-N 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester Chemical compound C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-UHFFFAOYSA-N 0.000 claims 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims 4
- 239000000194 fatty acid Substances 0.000 claims 4
- 229930195729 fatty acid Natural products 0.000 claims 4
- 150000004665 fatty acids Chemical class 0.000 claims 4
- 239000003149 muscarinic antagonist Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 229940125369 inhaled corticosteroids Drugs 0.000 claims 2
- 229940125389 long-acting beta agonist Drugs 0.000 claims 2
- 238000009827 uniform distribution Methods 0.000 claims 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- ANGKOCUUWGHLCE-HKUYNNGSSA-N [(3s)-1,1-dimethylpyrrolidin-1-ium-3-yl] (2r)-2-cyclopentyl-2-hydroxy-2-phenylacetate Chemical compound C1[N+](C)(C)CC[C@@H]1OC(=O)[C@](O)(C=1C=CC=CC=1)C1CCCC1 ANGKOCUUWGHLCE-HKUYNNGSSA-N 0.000 claims 1
- WOVFJBGKJQEQQD-UHFFFAOYSA-N acridine;hydrobromide Chemical compound [Br-].C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 WOVFJBGKJQEQQD-UHFFFAOYSA-N 0.000 claims 1
- 230000001022 anti-muscarinic effect Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229960004436 budesonide Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 claims 1
- 229960001469 fluticasone furoate Drugs 0.000 claims 1
- 229960000289 fluticasone propionate Drugs 0.000 claims 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 1
- 229960002848 formoterol Drugs 0.000 claims 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 1
- 229960004078 indacaterol Drugs 0.000 claims 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 claims 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 claims 1
- 229960002744 mometasone furoate Drugs 0.000 claims 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 1
- 150000004682 monohydrates Chemical group 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- YZNWXXJZEDHRKB-UHFFFAOYSA-N octadecyl 2-hydroxypropanoate;sodium Chemical compound [Na].CCCCCCCCCCCCCCCCCCOC(=O)C(C)O YZNWXXJZEDHRKB-UHFFFAOYSA-N 0.000 claims 1
- 229960004286 olodaterol Drugs 0.000 claims 1
- COUYJEVMBVSIHV-SFHVURJKSA-N olodaterol Chemical compound C1=CC(OC)=CC=C1CC(C)(C)NC[C@H](O)C1=CC(O)=CC2=C1OCC(=O)N2 COUYJEVMBVSIHV-SFHVURJKSA-N 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 229960000257 tiotropium bromide Drugs 0.000 claims 1
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 4
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15194660.5 | 2015-11-16 | ||
| EP15194660 | 2015-11-16 | ||
| PCT/EP2016/077558 WO2017085004A1 (en) | 2015-11-16 | 2016-11-14 | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501876A JP2019501876A (ja) | 2019-01-24 |
| JP2019501876A5 true JP2019501876A5 (cg-RX-API-DMAC7.html) | 2019-12-19 |
| JP6963548B2 JP6963548B2 (ja) | 2021-11-10 |
Family
ID=54548062
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018524832A Active JP6963548B2 (ja) | 2015-11-16 | 2016-11-14 | 抗コリン作用薬、コルチコステロイド及びβ−アドレナリン作用薬を含む乾燥粉末製剤を調製するための方法 |
Country Status (35)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10350164B2 (en) | 2017-05-11 | 2019-07-16 | Chiesi Farmaceutici S.P.A. | Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
| WO2018206618A1 (en) * | 2017-05-11 | 2018-11-15 | Chiesi Farmaceutici S.P.A. | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
| US11433063B1 (en) | 2019-03-12 | 2022-09-06 | Belhaven Biopharma, Inc. | Intranasal composition of pharmaceutical countermeasures for chemical warfare nerve agents and accidental exposure to organophosphate pesticides |
| WO2020198716A1 (en) * | 2019-03-27 | 2020-10-01 | Kemin Industries, Inc. | Methods for preparing metal carboxylates in one-pot reaction |
| CN112137957B (zh) * | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
| WO2021143785A1 (zh) * | 2020-01-15 | 2021-07-22 | 四川海思科制药有限公司 | 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法 |
| WO2022045995A1 (en) * | 2020-08-28 | 2022-03-03 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | A process for the preparation of dry powder compositions for inhalation |
| US12178782B2 (en) * | 2021-03-24 | 2024-12-31 | Cmpd Licensing, Llc | Drug powderization within vials |
| WO2023117967A1 (en) | 2021-12-21 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Dry powder formulations filled in an inhaler with improved resistance to humidity |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
| ATE503517T2 (de) | 2002-07-31 | 2011-04-15 | Chiesi Farma Spa | Pulverinhalator |
| EA027778B1 (ru) * | 2009-12-23 | 2017-08-31 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Комбинированная терапия copd |
| KR20130111967A (ko) * | 2010-06-22 | 2013-10-11 | 키에시 파르마슈티시 엣스. 피. 에이. | 항무스카린성 약물을 포함하는 건조 분말 제제 |
| HUE037944T2 (hu) * | 2012-12-06 | 2018-09-28 | Chiesi Farm Spa | Muszkarin receptor antagonista és béta2 adrenerg receptor agonista akitvitással rendelkezõ vegyületek |
| TR201807091T4 (tr) * | 2012-12-06 | 2018-06-21 | Chiesi Farm Spa | Radyasyon veya kemoterapi̇ye bağli mukosi̇ti̇n önlenmesi̇ i̇çi̇n bi̇r kombi̇nasyonun kullanimi. |
| US9393202B2 (en) | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
| NZ715797A (en) | 2013-07-11 | 2020-06-26 | Chiesi Farm Spa | Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation |
-
2016
- 2016-11-14 DK DK19205980.6T patent/DK3620176T3/da active
- 2016-11-14 EP EP19205980.6A patent/EP3620176B1/en active Active
- 2016-11-14 LT LTEP16801982.6T patent/LT3377108T/lt unknown
- 2016-11-14 TW TW105137048A patent/TWI731891B/zh active
- 2016-11-14 SI SI201631331T patent/SI3620176T1/sl unknown
- 2016-11-14 AU AU2016356858A patent/AU2016356858B2/en active Active
- 2016-11-14 MD MDE20200899T patent/MD3620176T2/ro unknown
- 2016-11-14 PT PT168019826T patent/PT3377108T/pt unknown
- 2016-11-14 PL PL19205936T patent/PL3628331T3/pl unknown
- 2016-11-14 LT LTEP19205980.6T patent/LT3620176T/lt unknown
- 2016-11-14 CN CN201680066801.5A patent/CN108289962B/zh active Active
- 2016-11-14 DK DK16801982.6T patent/DK3377108T3/da active
- 2016-11-14 SG SG11201804050QA patent/SG11201804050QA/en unknown
- 2016-11-14 MD MDE20180917T patent/MD3377108T2/ro unknown
- 2016-11-14 RS RS20211283A patent/RS62506B1/sr unknown
- 2016-11-14 KR KR1020187013286A patent/KR20180082443A/ko not_active Withdrawn
- 2016-11-14 RS RS20211196A patent/RS62404B1/sr unknown
- 2016-11-14 DK DK19205936.8T patent/DK3628331T3/da active
- 2016-11-14 WO PCT/EP2016/077558 patent/WO2017085004A1/en not_active Ceased
- 2016-11-14 UA UAA201805271A patent/UA125019C2/uk unknown
- 2016-11-14 EP EP19205936.8A patent/EP3628331B1/en active Active
- 2016-11-14 PT PT192059806T patent/PT3620176T/pt unknown
- 2016-11-14 ME MEP-2020-80A patent/ME03778B/me unknown
- 2016-11-14 ES ES19205980T patent/ES2891073T3/es active Active
- 2016-11-14 PL PL16801982T patent/PL3377108T3/pl unknown
- 2016-11-14 EP EP16801982.6A patent/EP3377108B1/en active Active
- 2016-11-14 JP JP2018524832A patent/JP6963548B2/ja active Active
- 2016-11-14 RS RS20200440A patent/RS60171B1/sr unknown
- 2016-11-14 AR ARP160103473A patent/AR106688A1/es not_active Application Discontinuation
- 2016-11-14 MD MDE20200898T patent/MD3628331T2/ro unknown
- 2016-11-14 MX MX2018005977A patent/MX379853B/es unknown
- 2016-11-14 ES ES16801982T patent/ES2783855T3/es active Active
- 2016-11-14 MA MA50487A patent/MA50487B1/fr unknown
- 2016-11-14 MY MYPI2018000704A patent/MY186229A/en unknown
- 2016-11-14 PE PE2018000973A patent/PE20181488A1/es unknown
- 2016-11-14 HU HUE19205936A patent/HUE056260T2/hu unknown
- 2016-11-14 HU HUE19205980A patent/HUE056441T2/hu unknown
- 2016-11-14 ES ES19205936T patent/ES2895687T3/es active Active
- 2016-11-14 SI SI201630682T patent/SI3377108T1/sl unknown
- 2016-11-14 HR HRP20211598TT patent/HRP20211598T1/hr unknown
- 2016-11-14 PL PL19205980T patent/PL3620176T3/pl unknown
- 2016-11-14 MA MA43256A patent/MA43256B1/fr unknown
- 2016-11-14 LT LTEP19205936.8T patent/LT3628331T/lt unknown
- 2016-11-14 PT PT192059368T patent/PT3628331T/pt unknown
- 2016-11-14 GE GEAP201614783A patent/GEP20207157B/en unknown
- 2016-11-14 HU HUE16801982A patent/HUE049751T2/hu unknown
- 2016-11-14 HR HRP20211600TT patent/HRP20211600T1/hr unknown
- 2016-11-14 SI SI201631349T patent/SI3628331T1/sl unknown
- 2016-11-14 EA EA201890966A patent/EA037716B1/ru unknown
- 2016-11-14 MA MA50488A patent/MA50488B1/fr unknown
- 2016-11-14 SG SG10201912093YA patent/SG10201912093YA/en unknown
- 2016-11-14 HR HRP20200537TT patent/HRP20200537T1/hr unknown
- 2016-11-15 US US15/351,562 patent/US10086004B2/en active Active
-
2018
- 2018-05-14 IL IL259329A patent/IL259329B/en active IP Right Grant
- 2018-05-14 CL CL2018001298A patent/CL2018001298A1/es unknown
- 2018-05-14 SA SA518391570A patent/SA518391570B1/ar unknown
- 2018-05-14 ZA ZA2018/03168A patent/ZA201803168B/en unknown
- 2018-05-15 PH PH12018501022A patent/PH12018501022B1/en unknown
- 2018-05-16 CO CONC2018/0005141A patent/CO2018005141A2/es unknown
- 2018-08-27 US US16/113,026 patent/US10772896B2/en active Active
-
2020
- 2020-04-06 CY CY20201100319T patent/CY1123042T1/el unknown
- 2020-08-07 US US16/987,695 patent/US10966991B2/en active Active
-
2021
- 2021-02-24 US US17/184,181 patent/US11628175B2/en active Active
- 2021-09-07 CY CY20211100793T patent/CY1124475T1/el unknown
- 2021-09-09 CY CY20211100797T patent/CY1124490T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501876A5 (cg-RX-API-DMAC7.html) | ||
| JP2018537453A5 (cg-RX-API-DMAC7.html) | ||
| HRP20200537T1 (hr) | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik | |
| RU2012145762A (ru) | Способ получения частиц с пониженным электростатическим зарядом | |
| HRP20200571T1 (hr) | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik | |
| JP2016512494A5 (cg-RX-API-DMAC7.html) | ||
| CN105412049B (zh) | 一种干粉吸入剂用药物组合物及其制备方法 | |
| PT1545634E (pt) | Método para preparar composições de pó seco para inalação | |
| JP2015519356A5 (cg-RX-API-DMAC7.html) | ||
| EP2682098B1 (en) | Inhalation Compositions | |
| US9682038B2 (en) | Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy | |
| JP2014518894A (ja) | ウメクリジニウムを含む乾燥粉末インヘラー組成物 | |
| KR102255402B1 (ko) | 건조 분말 흡입 조성물의 제조 방법 | |
| EP2682099B1 (en) | Dry Powder Inhaler Compositions Comprising Long Acting Muscorinic Antagonists | |
| AU2013275641B2 (en) | Method for producing powder for inhalation | |
| CN107496388B (zh) | 一种含有福莫特罗和噻托铵盐组合物的粉状制剂及其制备方法 | |
| EP2821062A1 (en) | Novel dry powder inhaler formulations | |
| JP5345605B2 (ja) | 乾燥粉末吸入組成物の製造方法 | |
| CN107213141A (zh) | 用于吸入的药物组合物 | |
| JP7712916B2 (ja) | 吸入用乾燥粉末製剤のための新規担体粒子 | |
| NZ742473B2 (en) | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | |
| NZ742474B2 (en) | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic | |
| JP6653323B2 (ja) | 吸入可能な製剤 | |
| JP2013177429A (ja) | 吸入組成物 | |
| WO2022146257A1 (en) | A process for the preparation of dry powder compositions for inhalation |